Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma

SIMPLE SUMMARY: Pancreatic adenocarcinoma (PDAC) is a disease with an incredibly grim prognosis. Most patients die within one year of receiving the diagnosis. There are currently very few tools to help the clinician decide between treatment options and evaluate prognosis at an individual level. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Stubbe, Benjamin Emil, Henriksen, Stine Dam, Madsen, Poul Henning, Larsen, Anders Christian, Krarup, Henrik Bygum, Pedersen, Inge Søkilde, Johansen, Martin Nygård, Thorlacius-Ussing, Ole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616084/
https://www.ncbi.nlm.nih.gov/pubmed/34830873
http://dx.doi.org/10.3390/cancers13225717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616084/
https://www.ncbi.nlm.nih.gov/pubmed/34830873
http://dx.doi.org/10.3390/cancers13225717

Ejemplares similares